In a strategic move to diversify beyond aquaculture, Growel Formulations Pvt Ltd has announced its entry into the poultry sector through an investment in Provet Pharma Private Limited. While the financial details remain undisclosed, the deal marks a significant expansion of Growel’s footprint in animal health and nutrition.
Provet Pharma, established in 2009 by veterinary professionals V Muthu Selvan and S Senthil, has built a strong presence in poultry healthcare, offering preventive and therapeutic solutions. The company also has a growing footprint in aquaculture and has recently ventured into export markets.
Growel stated that the investment aligns with its long-term vision of building a diversified, science-driven platform focused on animal nutrition, health, and wellness. The poultry segment, being one of the fastest-growing protein industries, presents significant opportunities driven by rising demand, advancements in feed technology, and increasing emphasis on productivity and animal health.
The transaction was facilitated by Deloitte India, which acted as the buy-side advisor to Growel, while Veda Corporate Advisors advised Provet Pharma.
With this partnership, the combined platform is expected to enhance product offerings and strengthen its value proposition for farmers and integrators across poultry and aquaculture segments. The move also complements Growel Group’s broader diversification strategy, following its recent foray into the pet nutrition segment.
This development underscores a growing trend of cross-sector expansion within the animal health industry, as companies seek integrated, multi-species solutions to drive future growth.
